ATE289294T1 - Pyrrolidin-derivate als faktor xa inhibitoren - Google Patents
Pyrrolidin-derivate als faktor xa inhibitorenInfo
- Publication number
- ATE289294T1 ATE289294T1 AT02738368T AT02738368T ATE289294T1 AT E289294 T1 ATE289294 T1 AT E289294T1 AT 02738368 T AT02738368 T AT 02738368T AT 02738368 T AT02738368 T AT 02738368T AT E289294 T1 ATE289294 T1 AT E289294T1
- Authority
- AT
- Austria
- Prior art keywords
- inhibitors
- factor
- pyrrolidine derivatives
- pyrrolidine
- derivatives
- Prior art date
Links
- 229940123583 Factor Xa inhibitor Drugs 0.000 title 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical class C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0114005.2A GB0114005D0 (en) | 2001-06-08 | 2001-06-08 | Chemical compounds |
| PCT/GB2002/002721 WO2002100830A1 (en) | 2001-06-08 | 2002-06-06 | Pyrrolidine derivatives as factor xa inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE289294T1 true ATE289294T1 (de) | 2005-03-15 |
Family
ID=9916209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02738368T ATE289294T1 (de) | 2001-06-08 | 2002-06-06 | Pyrrolidin-derivate als faktor xa inhibitoren |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US7186717B2 (de) |
| EP (1) | EP1395553B1 (de) |
| JP (1) | JP4242274B2 (de) |
| KR (1) | KR100877245B1 (de) |
| CN (1) | CN1256324C (de) |
| AR (1) | AR036086A1 (de) |
| AT (1) | ATE289294T1 (de) |
| AU (1) | AU2002311451B2 (de) |
| BR (1) | BR0210207A (de) |
| CA (1) | CA2449629A1 (de) |
| CO (1) | CO5540285A2 (de) |
| CZ (1) | CZ20033325A3 (de) |
| DE (1) | DE60203006T2 (de) |
| DK (1) | DK1395553T3 (de) |
| ES (1) | ES2235050T3 (de) |
| GB (1) | GB0114005D0 (de) |
| HU (1) | HUP0400156A3 (de) |
| IL (1) | IL159195A0 (de) |
| MX (1) | MXPA03011384A (de) |
| MY (1) | MY136859A (de) |
| NO (1) | NO326689B1 (de) |
| NZ (1) | NZ530004A (de) |
| PL (1) | PL368082A1 (de) |
| PT (1) | PT1395553E (de) |
| SI (1) | SI1395553T1 (de) |
| TW (1) | TWI298719B (de) |
| WO (1) | WO2002100830A1 (de) |
| ZA (1) | ZA200309367B (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0114005D0 (en) * | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
| GB0130705D0 (en) * | 2001-12-21 | 2002-02-06 | Glaxo Group Ltd | Chemical compounds |
| GB0228533D0 (en) * | 2002-12-06 | 2003-01-15 | Glaxo Group Ltd | Crystalline form |
| GB0228552D0 (en) * | 2002-12-06 | 2003-01-15 | Glaxo Group Ltd | Chemical compounds |
| US20050119266A1 (en) * | 2003-10-01 | 2005-06-02 | Yan Shi | Pyrrolidine and piperidine derivatives as factor Xa inhibitors |
| ATE533491T1 (de) | 2004-09-21 | 2011-12-15 | Trobio Ab | Stabilisierte protease zusammensetzungen enthaltend eine serinprotease, morpholin-derivate und reversible serinprotease- inhibitoren |
| WO2006047415A2 (en) * | 2004-10-26 | 2006-05-04 | Janssen Pharmaceutica, N.V. | Factor xa compounds |
| WO2006110726A2 (en) * | 2005-04-11 | 2006-10-19 | Glaxo Group Limited | Dosage formulations and methods of treatment and prevention |
| AU2005336535B2 (en) * | 2005-09-22 | 2012-05-24 | Trobio Ab | Stabilized protease composition |
| CN102380100A (zh) * | 2005-09-22 | 2012-03-21 | 特罗比奥股份公司 | 稳定的蛋白酶组合物 |
| DE102007028407A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE102007028319A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE102007028406A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| US9637479B2 (en) * | 2013-04-26 | 2017-05-02 | Sanofi | Tartrate salt of 5-chloro-thiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxo-pyrrolidin-1-yl)-benzenesulfonylamino]-3-(4-methyl-piperazin-1-yl)-3-oxo-propyl]amide |
| DE102014108210A1 (de) | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
| EP3078378B1 (de) | 2015-04-08 | 2020-06-24 | Vaiomer | Verwendung von faktor-xa-inhibitoren zur regulierung von glykämie |
| EP4070658A1 (de) | 2021-04-06 | 2022-10-12 | BIORoxx GmbH | Verwendung von blutgerinnungshemmenden verbindungen als rodentizide |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL92011A0 (en) | 1988-10-19 | 1990-07-12 | Abbott Lab | Heterocyclic peptide renin inhibitors |
| DE4035961A1 (de) * | 1990-11-02 | 1992-05-07 | Thomae Gmbh Dr K | Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| DE4121947A1 (de) * | 1991-07-03 | 1993-01-07 | Basf Ag | 2-(3-(4-amidino-phenyl))-propionsaeurederivate, ihre herstellung und verwendung |
| US5703208A (en) * | 1994-06-17 | 1997-12-30 | Corvas International, Inc. | 3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors |
| JP2001504810A (ja) | 1996-10-11 | 2001-04-10 | シーオーアール・セラピューティックス・インコーポレーテッド | 選択的第Ｘａ因子阻害剤 |
| IL130152A0 (en) | 1996-12-13 | 2000-06-01 | Rhone Poulenc Rorer Pharma | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclyamide compounds |
| US6281227B1 (en) | 1996-12-13 | 2001-08-28 | Aventis Pharma Deutschland Gmbh | Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds |
| US6602864B1 (en) | 1996-12-13 | 2003-08-05 | Aventis Pharma Deutschland Gmbh | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds |
| US6187797B1 (en) * | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
| IL123986A (en) | 1997-04-24 | 2011-10-31 | Organon Nv | Medicinal compounds |
| KR20010015639A (ko) * | 1997-09-30 | 2001-02-26 | 스즈키 다다시 | 술포닐 유도체 |
| TR200002182T2 (tr) | 1998-01-27 | 2000-12-21 | Aventis Pharmaceuticals Products Inc. | İkame edilmiş aksozaherosayklil faktör xa inhibitörleri |
| US6281277B1 (en) | 1998-04-22 | 2001-08-28 | Showa Denko Kabushiki Kaisha | Homogeneously surface-fluorinated metal oxide particulates, process for manufacturing the same, and use of the same |
| EP1150976B1 (de) | 1998-12-31 | 2003-02-26 | Aventis Pharmaceuticals Inc. | 3-(thio-substituierte amido)-lactame, verwendbar als inhibitoren der matrix-metalloproteinase |
| AU756174B2 (en) | 1999-02-09 | 2003-01-09 | Bristol-Myers Squibb Company | Lactam inhibitors of FXa and method |
| AU3192500A (en) * | 1999-03-16 | 2000-10-04 | C & C Research Laboratories | Substituted proline derivatives and medicinal compositions containing the same |
| AU4431400A (en) | 1999-05-12 | 2000-12-05 | Japan As Represented By President Of National Cancer Center | Anticancer agents containing ep1 antagonists as the active ingredient |
| CN1420882A (zh) | 1999-07-28 | 2003-05-28 | 阿温蒂斯药物公司 | 取代的氧代氮杂杂环基化合物 |
| JP2004518688A (ja) | 2001-01-30 | 2004-06-24 | ブリストル−マイヤーズ スクイブ カンパニー | ファクターＸａ阻害剤のスルホンアミドラクタムおよびその方法 |
| GB0114004D0 (en) * | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
| GB0114005D0 (en) * | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
| GB0228533D0 (en) * | 2002-12-06 | 2003-01-15 | Glaxo Group Ltd | Crystalline form |
| GB0228552D0 (en) * | 2002-12-06 | 2003-01-15 | Glaxo Group Ltd | Chemical compounds |
-
2001
- 2001-06-08 GB GBGB0114005.2A patent/GB0114005D0/en not_active Ceased
-
2002
- 2002-06-06 PT PT02738368T patent/PT1395553E/pt unknown
- 2002-06-06 SI SI200230101T patent/SI1395553T1/xx unknown
- 2002-06-06 MY MYPI20022097A patent/MY136859A/en unknown
- 2002-06-06 JP JP2003503599A patent/JP4242274B2/ja not_active Expired - Fee Related
- 2002-06-06 AR ARP020102128A patent/AR036086A1/es unknown
- 2002-06-06 DE DE60203006T patent/DE60203006T2/de not_active Expired - Lifetime
- 2002-06-06 IL IL15919502A patent/IL159195A0/xx unknown
- 2002-06-06 NZ NZ530004A patent/NZ530004A/en unknown
- 2002-06-06 PL PL02368082A patent/PL368082A1/xx unknown
- 2002-06-06 KR KR1020037016070A patent/KR100877245B1/ko not_active Expired - Fee Related
- 2002-06-06 AU AU2002311451A patent/AU2002311451B2/en not_active Ceased
- 2002-06-06 CZ CZ20033325A patent/CZ20033325A3/cs unknown
- 2002-06-06 AT AT02738368T patent/ATE289294T1/de not_active IP Right Cessation
- 2002-06-06 WO PCT/GB2002/002721 patent/WO2002100830A1/en not_active Ceased
- 2002-06-06 EP EP02738368A patent/EP1395553B1/de not_active Expired - Lifetime
- 2002-06-06 TW TW091112153A patent/TWI298719B/zh active
- 2002-06-06 US US10/479,545 patent/US7186717B2/en not_active Expired - Fee Related
- 2002-06-06 DK DK02738368T patent/DK1395553T3/da active
- 2002-06-06 CA CA002449629A patent/CA2449629A1/en not_active Abandoned
- 2002-06-06 MX MXPA03011384A patent/MXPA03011384A/es active IP Right Grant
- 2002-06-06 BR BR0210207-2A patent/BR0210207A/pt not_active Application Discontinuation
- 2002-06-06 CN CNB028154002A patent/CN1256324C/zh not_active Expired - Fee Related
- 2002-06-06 ES ES02738368T patent/ES2235050T3/es not_active Expired - Lifetime
- 2002-06-06 HU HU0400156A patent/HUP0400156A3/hu unknown
-
2003
- 2003-12-02 ZA ZA200309367A patent/ZA200309367B/en unknown
- 2003-12-05 NO NO20035440A patent/NO326689B1/no not_active IP Right Cessation
- 2003-12-05 CO CO03107408A patent/CO5540285A2/es not_active Application Discontinuation
-
2006
- 2006-10-11 US US11/548,395 patent/US7429587B2/en not_active Expired - Fee Related
- 2006-10-11 US US11/548,404 patent/US7326785B2/en not_active Expired - Fee Related
- 2006-10-11 US US11/548,402 patent/US7517879B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20042592L (no) | Indol-2-karboksamider som faktor XA inhibitorer | |
| NO20021230D0 (no) | Inhibitorer for faktor Xa | |
| NO20041163L (no) | Laktam-inneholdende forbindelser og derivater derav som faktor XA-inhibitorer | |
| ATE444292T1 (de) | Pyrazolderivate als faktor-xa-inhibitoren | |
| AU2002350217A8 (en) | Glycinamides as factor xa inhibitors | |
| EP1684744A4 (de) | Pyrrolidin- und piperidin-derivate als faktor-xa-hemmer | |
| ATE437862T1 (de) | Pyrimidin-5-onderivate als ldl-pla2 inhibitoren | |
| ATE441631T1 (de) | Phenylpiperidinderivate als serotonin- wiederaufnahmehemmer | |
| DE60329282D1 (de) | Cyano-pyrrolidine als DPP-IV Inhibitoren | |
| DE60315862D1 (de) | Dihydropyridinonderivate als hne-inhibitoren | |
| DE60123294D1 (de) | Diazepan Derivate als Faktor X Inhibitor | |
| ATE289294T1 (de) | Pyrrolidin-derivate als faktor xa inhibitoren | |
| AU2002365896A8 (en) | Substituted amino methyl factor xa inhibitors | |
| DE60008524D1 (de) | Furanonderivate als inhibitoren von cathepsin s | |
| DE60203529D1 (de) | Indolderivate als cox-ii-inhibitoren | |
| ATE330940T1 (de) | Pyrrolidin-derivate verwendbar als bax- inhibitoren | |
| NO20042990L (no) | Pyrrolidin-2-oner som faktor XA inhibitorer | |
| NO20014234D0 (no) | Pyrazol-3-on-derivater som faktor-Xa-inhibitorer | |
| ATE305452T1 (de) | Faktor xa inhibitor | |
| ATE401322T1 (de) | Imidazolderivate als faktor-xa-inhibitoren | |
| ATE474838T1 (de) | Benzimidazolderivate als faktor xa-inhibitoren | |
| DE502004012284D1 (de) | Carbonsäureamidderivate und ihre verwendung als faktor xa inhibitoren | |
| DE502004011365D1 (de) | Ethynylderivate als faktor xa-inhibitoren | |
| TH0201003138B (th) | สารประกอบที่มีแลคแตมและอนุพันธ์ของสิ่งเหล่านี้เป็นตัวยับยั้งปัจจัย Xa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1395553 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |